European Innovation Council

Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

AMT Medical B.V., founded in 2015 and based in Ede, the Netherlands, specializes in developing innovative devices for heart bypass surgery. The company has created the AMT Heart Bypass System, which utilizes the ELANA bypass technique, originally developed by neurosurgeon Prof. Dr. C.A.F. Tulleken and his team. This minimal invasive approach aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, ultimately improving patient outcomes and recovery times. The AMT Heart Bypass System has completed its development and production processes, as well as all pre-clinical trials. A clinical multi-center trial is set to begin in late 2019 or early 2020, marking a significant step in bringing this advanced technology to the medical community.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, specializing in the development of advanced imaging devices for medical applications using quantum dot technology. The company focuses on creating X-ray sensors that deliver high-contrast and high-resolution mammograms, allowing for improved diagnostic capabilities while minimizing radiation exposure for patients. QDI Systems emphasizes user-friendliness by providing accessible quantum dot materials along with comprehensive instructions for constructing high-performance imaging devices. This approach enables healthcare professionals to obtain precise medical images, enhancing the overall efficacy of diagnostic procedures.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, specializing in the development of advanced imaging devices for medical applications using quantum dot technology. The company focuses on creating X-ray sensors that deliver high-contrast and high-resolution mammograms, allowing for improved diagnostic capabilities while minimizing radiation exposure for patients. QDI Systems emphasizes user-friendliness by providing accessible quantum dot materials along with comprehensive instructions for constructing high-performance imaging devices. This approach enables healthcare professionals to obtain precise medical images, enhancing the overall efficacy of diagnostic procedures.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Patient-specific right heart pumps that free patients from heavy battery packages and increase patient's quality of life.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its Trillium™ technology, designed to provide functional tricuspid valve replacement through cross-caval anchoring and a unique multi-valve design. This technology aims to regulate blood flow effectively, thereby enhancing both the lifespan and quality of life for patients. Innoventric has successfully completed over ten implantations of the Trillium™ technology as part of its first clinical trial in Europe and maintains a robust patent portfolio covering its key innovations in tricuspid treatment.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Vitestro is a company focused on enhancing patient care through innovative autonomous blood drawing technology. It develops medical robotic devices tailored for use in hospitals and clinical laboratories. The company’s key product utilizes multi-dimensional ultrasound to detect nerves and arteries, leveraging deep learning to minimize the risk of arterial complications during blood draws. This advanced technology not only aids healthcare professionals in performing procedures with greater precision but also aims to improve overall patient health outcomes by reducing complications associated with traditional blood collection methods.

Vitestro is a company focused on enhancing patient care through innovative autonomous blood drawing technology. It develops medical robotic devices tailored for use in hospitals and clinical laboratories. The company’s key product utilizes multi-dimensional ultrasound to detect nerves and arteries, leveraging deep learning to minimize the risk of arterial complications during blood draws. This advanced technology not only aids healthcare professionals in performing procedures with greater precision but also aims to improve overall patient health outcomes by reducing complications associated with traditional blood collection methods.

Sentante is a medical device company focused on developing robotic teleoperated systems specifically for endovascular procedures. By utilizing this innovative technology, Sentante enables physicians to perform surgeries remotely, significantly reducing their exposure to harmful X-rays. The company has designed a manipulator that assists endovascular practitioners in conducting procedures with minimal radiation risk, promoting safer practices in the medical field. Additionally, Sentante's robotic systems facilitate minimally invasive coronary procedures, enhancing the ability of surgeons to carry out complex endovascular surgeries while also contributing to a decrease in oncological diseases among healthcare personnel.

Quantum Diamonds specializes in the development of nitrogen-vacancy (NV) diamonds for quantum sensing applications. The company offers advanced quantum sensors that measure magnetic fields, temperature, and pressure, providing superior sensitivity and resolution compared to traditional sensors. These sensors are designed for use in various fields, including navigation, bio-imaging, geographical surveying, and spectroscopy, even under challenging conditions. By focusing on atom-sized quantum technologies, Quantum Diamonds enables industries and academic institutions to conduct precise analyses, optimizing for factors such as crystal lattice strain and charge state stability.

RespiQ is a healthtech startup that specializes in portable, non-invasive breath analysis technology aimed at the early detection and management of respiratory diseases. By utilizing advanced emission spectroscopy and artificial intelligence, RespiQ's device identifies volatile organic compounds (VOCs) in breath, enabling real-time detection of conditions such as COPD exacerbations. The company's focus on affordability, portability, and user-friendliness seeks to democratize access to advanced diagnostics, ultimately improving patient outcomes and reducing healthcare costs. In addition to respiratory diseases, RespiQ's versatile platform has potential applications for asthma, lung cancer, and infectious diseases. The company also offers an app that provides personalized health insights and dietary guidance, allowing users to monitor their health proactively. RespiQ's combination of technical and healthcare expertise positions it as a leader in breath diagnostics, with a commitment to enhancing overall health and well-being.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques, including Google's TensorFlow, to enhance the diagnosis of brain-related diseases, particularly acute stroke. The platform facilitates timely and universal diagnosis by using non-contrast CT imaging, which eliminates the need for contrast CT scans and significantly reduces time-to-treatment. This capability enables radiologists to effectively communicate with hospitals, stroke units, and other healthcare professionals, thereby improving the overall clinical response to stroke cases. By focusing on specific pathologies, Methinks aims to achieve clinical excellence in the diagnosis and management of neurological conditions.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Microsure is a medical device company based in Eindhoven, The Netherlands, founded in 2014. It specializes in developing innovative solutions for microsurgery, a field that operates at the limits of physical capabilities. The company's flagship product is a motion stabilizer system designed specifically for microsurgeons, which enhances surgical precision by filtering out tremors and providing exceptional control during procedures. This technology allows for hybrid microsurgical procedures that enable surgeons to utilize their own instruments, thereby reducing costs for hospitals. The Microsure motion stabilizer has demonstrated its effectiveness in clinical trials, including successful operations for lymphedema. By improving the quality of microsurgical procedures, the company aims to expand treatment options for patients and facilitate the development of new, highly accurate surgical techniques.

Ligence is a Deep Tech startup based in Lithuania, specializing in healthcare solutions developed by a team of medical doctors proficient in artificial intelligence. The company focuses on automating heart ultrasound image analysis through its flagship product, Ligence Heart. This technology employs deep learning algorithms to accurately recognize various heart image views and perform essential measurements automatically. By streamlining the analysis process, Ligence Heart allows physicians to bypass manual measurements, enabling cardiologists and sonographers to enhance efficiency and significantly reduce analysis time, thereby allowing them to concentrate more on patient care and treatment.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Rockfield Medical Devices is a small to medium-sized enterprise focused on transforming the enteral feeding market through innovative design and user-centered solutions. Founded by a team of experts in the medical device industry and research, the company aims to enhance the mobility and quality of life for individuals relying on tube feeding. Rockfield's platform introduces a lightweight and discreet mobile feeding system that significantly improves user experience while reducing technical support and maintenance costs for sales partners. Through its commitment to innovation and usability, Rockfield strives to deliver exemplary satisfaction to end users in the enteral feeding community.

Trisol Medical specializes in developing innovative medical devices for the treatment of tricuspid regurgitation. The company focuses on its transcatheter tricuspid replacement valve, which features a nitinol frame and specially designed leaflets aimed at effectively addressing tricuspid regurgitation while preserving the function of the right ventricle. Through its advanced technology, Trisol Medical offers comprehensive solutions for managing tricuspid regurgitation and right ventricle dysfunction, enhancing patient outcomes in the field of cardiac care.

Neuro Event Labs Oy is a Finnish medical technology company founded in 2015 and based in Tampere. The company specializes in developing artificial intelligence-powered software that monitors epilepsy patients both at home and in clinical settings. Its primary product collects and analyzes accurate data on epilepsy seizures through the use of video and various sensors, leveraging computer vision, smart analytics, and machine learning. This data is relayed to healthcare providers, allowing them to make informed treatment decisions tailored to individual patients. The solution has been crafted in collaboration with leading hospitals in Finland, enhancing its reliability and effectiveness in managing epilepsy care.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

CarThera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices aimed at treating brain disorders. The company has created the SonoCloud®, an intracranial ultrasound implant that works in conjunction with a microbubble agent administered intravenously. This combination temporarily opens the blood-brain barrier, allowing for a significantly increased concentration of therapeutic molecules to penetrate the brain. By enhancing the delivery of treatments, CarThera's technology offers potential solutions for debilitating neurological conditions, providing healthcare professionals with new avenues for patient care.

Escala Medical is focused on developing a minimally invasive medical device aimed at treating pelvic organ prolapse (POP) in women. The company's innovative system offers a nonsurgical, incision-free, and mesh-free repair option that addresses the vaginal apex by connecting it to the sacrospinous ligament. This approach is designed to be safe, quick, and to preserve organ functionality while minimizing patient discomfort. The procedure can be performed in outpatient and office-based settings, providing a much-needed alternative for women suffering from POP.

Escala Medical is focused on developing a minimally invasive medical device aimed at treating pelvic organ prolapse (POP) in women. The company's innovative system offers a nonsurgical, incision-free, and mesh-free repair option that addresses the vaginal apex by connecting it to the sacrospinous ligament. This approach is designed to be safe, quick, and to preserve organ functionality while minimizing patient discomfort. The procedure can be performed in outpatient and office-based settings, providing a much-needed alternative for women suffering from POP.

Scandinavian Real Heart is a medical technology company focused on developing an innovative artificial heart designed to assist patients awaiting heart transplants. Their Total Artificial Heart (TAH) closely mimics the natural pumping mechanics, pressure ratios, and pulse of a healthy heart, aiming to provide improved functionality compared to existing options in the market. This device serves primarily as a transitional solution for individuals on the transplant waiting list, with the potential to save lives by addressing the urgent need for effective cardiac support.

Agade specializes in the development of robotic exoskeletons aimed at reducing muscle fatigue and minimizing the risk of injuries linked to repetitive and dynamic tasks. Their flagship product, AGADEXO, is designed to provide variable support for upper limb movements, effectively counteracting the effects of gravity and allowing for more efficient motion, akin to operating in a zero-gravity environment. The exoskeleton is compact and energy-efficient, consuming minimal power comparable to that of medium-intensity LED bulbs. This innovative technology is particularly beneficial for operators engaged in pick and place tasks, enhancing productivity while safeguarding against the physical strain associated with their work.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

Bluedrop Medical, established in 2014 and headquartered in Galway, Ireland, specializes in the development, manufacturing, and commercialization of an IoT-enabled device for early detection of diabetic foot ulcers. Their home-based system scans patients' feet daily, transmitting data to the cloud for analysis via advanced algorithms, which can identify skin abnormalities. This innovative solution aims to reduce the risk of amputation and improve the lives of diabetic patients, with a significant potential market given that up to 25% of diabetics may develop foot ulcers.

Nemysis Limited is a specialty pharmaceutical company based in Dublin, Ireland, founded in 2005. The company focuses on addressing unmet needs in nutritional disorders and deficiencies through a staged approach to product development. Nemysis manufactures food supplements, medical matrix products, and prescription items, targeting the same conditions across different market segments. Among its innovative offerings are a gastric and trypsin-resistant glutenous product for oral enzymatic therapy aimed at celiac disease patients, as well as an iron supplement designed to minimize gastrointestinal side effects associated with iron supplementation. Additionally, the company is developing a glutenous medical device that effectively destroys gluten, helping to prevent symptoms in individuals with celiac disease and non-celiac gluten sensitivity.

Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.

Syntach is a medical device company focused on improving the care of individuals with heart failure through the development of a cardiac support device. This innovative device aims to restore the impaired movement of the mitral valve and provide natural support to the heart. Syntach offers a permanent, active implant that can be inserted using a minimally invasive technique, making it smaller than existing left ventricular assist devices (LVADs). This design not only enhances the quality of life for patients but also reduces the risk of complications, benefiting both men and women who require cardiac support.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

iThera Medical specializes in advanced biomedical imaging technology, focusing on photonic molecular imaging. Founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, the company collaborates with this research center to enhance its proprietary Multi-Spectral Optoacoustic Tomography (MSOT) technology. This innovative approach provides real-time visualization of anatomical, functional, and molecular information within living tissue, which aids in the detection of tumors and inflammatory diseases. By enabling non-invasive diagnostic capabilities, iThera Medical supports both preclinical and clinical applications, offering significant advancements in medical imaging and patient care.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

AVATAR MEDICAL specializes in developing a virtual reality platform that creates 3D patient avatars from medical images. This innovative technology assists surgeons in visualizing complex medical data, evaluating surgical options, and enhancing training for medical fellows. By providing accurate and interactive representations of patients, the platform enables clinicians to better comprehend critical clinical information, ultimately improving the decision-making process in surgical planning. Additionally, AVATAR MEDICAL's approach fosters greater engagement with patients, allowing them to better understand their medical conditions and treatment options.

Gold Standard Phantoms specializes in the development, marketing, and sale of calibration services and devices for quantitative medical imaging, particularly focusing on MRI scanners. The company provides a cloud-based data analysis platform that ensures the calibration of images is traceable to standardized values. Its innovative cylindrical phantom design addresses the need for multiple sample vials during phantom preparation, allowing clinicians, medical physicists, and radiographers to obtain reproducible quantitative measurements of diseases across different patients, scanners, and clinics. This approach not only enhances the accuracy of MRI imaging but also holds the potential to reduce medical costs over time.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

Afon Technology specializes in developing non-invasive blood glucose monitoring devices aimed at improving the management of diabetes. Their innovative technology allows users to convert any smartwatch into a glucose monitoring device that provides real-time tracking of blood glucose levels, including high and low alerts. The devices offer fast and accurate measurements, data logging, and personalized health trend analysis, which help users monitor their condition effectively. Additionally, Afon Technology's solutions feature Bluetooth connectivity to smart devices, enabling compatibility with both iOS and Android platforms. This user-friendly approach enhances the quality of daily diabetes management and helps reduce the risk of complications associated with the condition.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Newronika is a company focused on restoring brain and body functions through innovative neuro-modulation technologies. It develops therapeutic devices that utilize a retro-activity system to record brain activity and modulate neuro-stimulation. By collecting, analyzing, and interpreting bio-signals, Newronika enables patients to receive timely stimulation, allowing them to engage in normal daily activities and enhance their quality of life. As a spin-off from prominent Italian research institutions, including the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika benefits from a multidisciplinary team of experts in various fields such as neuroscience, neurophysiology, biomedical engineering, and neuropsychology.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

CYTO365 specializes in the design and manufacturing of intravenous inlets, specifically the RondelO multi inlet stopcock. This product is intended for integration into IV sets to address drug incompatibility issues that can arise during parallel infusion. The company’s patented Luer inlets feature an automatic flushing mechanism, ensuring that a flushing fluid is readily available. This design provides an additional layer of security for drug administration by preventing the mixing of incompatible medications and facilitating effective rinsing of the infusion tube. Through its innovative solutions, CYTO365 aims to enhance patient safety during infusion therapy.

Akknatek specializes in developing innovative optical testing products aimed at improving postoperative management of intraocular lenses (IOLs). The company's patented lens reviewer technology enhances patients' visual outcomes, particularly for those experiencing dislocated IOLs following cataract surgery. By providing clear protocols for treatment, the lens reviewer minimizes the risk of unexpected refractive complications and decreases the need for additional refractive procedures. This streamlined approach to postoperative monitoring not only aids clinics in managing IOL placements but also fosters greater confidence in IOL implantations, ultimately benefiting patient care and outcomes.

Vigor Medical Technologies Ltd. focuses on developing and commercializing innovative devices aimed at treating chest trauma and facilitating thoracic and abdominal drainage. With over four million cases of chest trauma reported annually, which is a leading cause of accidental death, Vigor's products address a critical healthcare need. The company offers self-fixation sealing devices that prevent lung and heart collapse, essential for immediate and effective medical management. Additionally, Vigor has developed a hermetic seal and open drainage shaft that effectively seals wounds against contamination from dirt, blood, cloth, or hair, while also preventing both internal and external bleeding. These features make Vigor's devices valuable for military and civilian first aid organizations, as well as hospitals, enhancing the efficacy of emergency care in critical situations.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human beings using advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed Alya Red, a suite of simulation tools designed for the medical device and pharmaceutical industries. Utilizing a Software-as-a-Service model, Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients. By integrating high-performance computing, computational biomechanics, and data analysis, ELEM's technology enables biomedical companies and clinicians to improve diagnoses, plan treatments, and optimize drug delivery and medical devices.

ValueBiotech Srl is a medical device company focused on developing robotic surgical tools that enhance laparoscopic techniques. Designed by practicing surgeons, these innovative tools integrate seamlessly into operating rooms, enabling surgeons to perform procedures through a single incision or natural orifices, resulting in a painless and scarless experience for patients. The company's mission is to improve clinical outcomes while ensuring safety and cost-effectiveness in surgical practices. By transforming traditional surgical methods, ValueBiotech aims to provide better healthcare solutions for millions of patients each year.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

CorTec is a developer and manufacturer focused on creating advanced medical devices for neuromodulation and brain-computer interfaces. The company has spent a decade on research and development, culminating in the innovative CorTec Brain Interchange™ System. This unique platform allows researchers and clinicians to devise novel therapies for neurological disorders. Central to this system are the °AirRay™ electrode arrays, which are laser-structured, soft, and flexible, ensuring a gentle fit to the brain's contours for reliable, permanent recordings. The implanted electronics, protected by biocompatible ceramic encapsulation, preprocess data and include a custom microchip developed with the University of Ulm. This microchip amplifies and digitizes neuronal signals across multiple channels, while eliminating the need for battery replacements through an external inductive power supply. Furthermore, CorTec provides additional support, services, and components related to the Brain Interchange System to Medtech companies and startups in the neurotechnology sector.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Alesi Surgical Ltd. specializes in the development and commercialization of laparoscopic surgical smoke handling systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2009 and based in Cardiff, United Kingdom, the company emerged as a spin-out from the Welsh Institute for Minimal Access Therapy, benefiting from direct access to experienced surgeons and surgical trainers. Alesi Surgical's innovative products are designed to be portable and applicable in both laparoscopic and robot-assisted surgeries. Utilizing electrostatic precipitation technology, these tools effectively eliminate surgical smoke, ensuring a clear visual field during procedures. Alesi Surgical distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia.

Precisis is a medical technology company based in Heidelberg, Germany, founded in 2004. The company focuses on developing innovative medical devices aimed at treating epilepsy and enhancing patients' quality of life. Their flagship product involves a device that delivers individualized brain stimulation through a surgical procedure. This device is precisely positioned beneath the scalp over the epileptic origin in the brain, allowing for targeted therapeutic currents to be directed at specific areas without direct contact with the brain. This approach aims to provide deep and focused stimulation to effectively manage epilepsy.

timeisbrain is a medical device for improving the diagnostics and prognostics of acute ischaemic stroke

Novus Diagnostics is focused on developing an innovative diagnostic device that addresses sepsis, a life-threatening condition caused by infections. The company's technology enables rapid detection and classification of pathogens directly from whole blood samples. By providing quick and automated pathogen identification in just minutes, Novus Diagnostics aims to enhance the ability of healthcare providers to treat patients efficiently and effectively, while also maintaining cost-effectiveness in the diagnostic process.

FEops is a pioneer in physics-based simulations specifically tailored for minimally invasive cardiovascular devices and procedures. The company develops advanced cardiac imaging technology that enhances personalized treatment for patients with structural heart disease. By utilizing artificial intelligence to conduct anatomical analyses, FEops provides data-driven insights that improve transcatheter valve procedures through personalized computer simulations. This approach offers medical device companies and healthcare professionals unique insights that streamline research and development processes, enhance procedural efficiency, and ultimately improve clinical outcomes and patient safety. Additionally, FEops supports medical specialists and physicians with patient-specific information, facilitating more effective treatments.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

VesselSens, headquartered in Bonn, Germany, specializes in medical technology. It develops and markets implantable sensor systems designed to detect restenosis, a common complication following stent implantation or balloon angioplasty. These wireless sensors, placed in coronary or peripheral arteries, monitor vascular constrictions in real-time, aiding doctors in timely diagnosis and treatment.

Ostoform Limited is a medical device company based in Dublin, Ireland, focused on improving skin health for individuals with ostomies. Founded in 2016 as a spin-out from the University of Limerick, Ostoform develops patented technologies aimed at managing and reducing skin complications associated with ostomies. The company's primary products include a mouldable seal that fits securely around the stoma and FLOWASSIST, which directs stoma output away from the skin. By effectively guiding the corrosive output into the ostomy bag, these products help prevent skin irritation and swelling, enhancing patient comfort and quality of life. Ostoform aims to become a global leader in the ostomy skin health market, leveraging its innovative solutions to address the needs of ostomy patients.

AVVie GmbH is a medical device startup dedicated to creating minimally invasive implants for heart valve repair, specifically targeting mitral regurgitation. This condition arises when the mitral valve leaflets fail to close properly, potentially leading to heart failure over time. The company's flagship product, the Mitral Butterfly® implant, is delivered via a catheter, allowing for a less invasive alternative to open-heart surgery. This approach not only shortens hospitalization times, thereby reducing costs, but also expands treatment options for patients who may not qualify for traditional surgery. The implant features a one-stage delivery system and a design that allows the valve leaflets to maintain normal function after implantation. The entire procedure for repairing the diseased valve is completed in under 12 minutes, offering significant advantages over competitors' more complex multiple-stage methods.

Fineheart is a France-based medical device company that specializes in innovative technologies aimed at addressing cardiovascular diseases. The company is developing an implantable cardiac device that is wirelessly powered and fully implantable, designed to provide mechanical circulatory support. This novel device optimizes cardiac output while preserving the heart's natural contractility, thereby enabling patients with heart failure to restore normal cardiac function and improve their quality of life. Fineheart's focus on advanced medical solutions positions it as a key player in the evolving landscape of cardiovascular care.

Fineheart is a France-based medical device company that specializes in innovative technologies aimed at addressing cardiovascular diseases. The company is developing an implantable cardiac device that is wirelessly powered and fully implantable, designed to provide mechanical circulatory support. This novel device optimizes cardiac output while preserving the heart's natural contractility, thereby enabling patients with heart failure to restore normal cardiac function and improve their quality of life. Fineheart's focus on advanced medical solutions positions it as a key player in the evolving landscape of cardiovascular care.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques, including Google's TensorFlow, to enhance the diagnosis of brain-related diseases, particularly acute stroke. The platform facilitates timely and universal diagnosis by using non-contrast CT imaging, which eliminates the need for contrast CT scans and significantly reduces time-to-treatment. This capability enables radiologists to effectively communicate with hospitals, stroke units, and other healthcare professionals, thereby improving the overall clinical response to stroke cases. By focusing on specific pathologies, Methinks aims to achieve clinical excellence in the diagnosis and management of neurological conditions.

Orixha specializes in the development of an innovative cooling device aimed at improving patient outcomes following cardiac arrest. This device utilizes a dedicated liquid ventilator that performs total liquid ventilation by filling the lungs with liquid perfluorocarbons. This method leverages the high gas solubility and large pulmonary surfaces to transform the lungs into an efficient heat exchange chamber with the bloodstream. By doing so, Orixha's technology helps protect vital organs from damage caused by reperfusion, thereby enhancing the prognosis for patients in critical conditions.

Nanordica Medical is an Estonian medical technology company specializing in the treatment of chronic wounds through its innovative nanotechnology. The company has developed a patented wound dressing that combines copper and silver in nanofibers, effectively removing infection and promoting healing. In addition to its human applications, Nanordica Medical has launched Ravimus Vet, a veterinary product designed for animal wounds. The company is focused on addressing hard-to-heal human wounds, such as diabetic foot ulcers, and has recently completed a clinical trial demonstrating superior efficacy results compared to traditional silver ions-based dressings. By utilizing its advanced nanotechnology, Nanordica Medical aims to provide a more effective antibacterial solution for a broader range of bacteria, including drug-resistant strains.

Akknatek specializes in developing innovative optical testing products aimed at improving postoperative management of intraocular lenses (IOLs). The company's patented lens reviewer technology enhances patients' visual outcomes, particularly for those experiencing dislocated IOLs following cataract surgery. By providing clear protocols for treatment, the lens reviewer minimizes the risk of unexpected refractive complications and decreases the need for additional refractive procedures. This streamlined approach to postoperative monitoring not only aids clinics in managing IOL placements but also fosters greater confidence in IOL implantations, ultimately benefiting patient care and outcomes.

CYTO365 specializes in the design and manufacturing of intravenous inlets, specifically the RondelO multi inlet stopcock. This product is intended for integration into IV sets to address drug incompatibility issues that can arise during parallel infusion. The company’s patented Luer inlets feature an automatic flushing mechanism, ensuring that a flushing fluid is readily available. This design provides an additional layer of security for drug administration by preventing the mixing of incompatible medications and facilitating effective rinsing of the infusion tube. Through its innovative solutions, CYTO365 aims to enhance patient safety during infusion therapy.

CorTec is a developer and manufacturer focused on creating advanced medical devices for neuromodulation and brain-computer interfaces. The company has spent a decade on research and development, culminating in the innovative CorTec Brain Interchange™ System. This unique platform allows researchers and clinicians to devise novel therapies for neurological disorders. Central to this system are the °AirRay™ electrode arrays, which are laser-structured, soft, and flexible, ensuring a gentle fit to the brain's contours for reliable, permanent recordings. The implanted electronics, protected by biocompatible ceramic encapsulation, preprocess data and include a custom microchip developed with the University of Ulm. This microchip amplifies and digitizes neuronal signals across multiple channels, while eliminating the need for battery replacements through an external inductive power supply. Furthermore, CorTec provides additional support, services, and components related to the Brain Interchange System to Medtech companies and startups in the neurotechnology sector.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

neuroClues is a medical technology company that offers an eye-tracking platform designed to assist practitioners in quantifying clinical examinations. The system extracts eye movement biomarkers, which aid neurologists in identifying Parkinsonian syndromes long before symptoms become apparent. By providing non-invasive and reliable biomarkers for central nervous system disorders, neuroClues enables healthcare professionals to detect neurological diseases early and monitor their progression effectively. This innovative approach aims to revolutionize the way neurological assessments are conducted, enhancing early diagnosis and patient care.

timeisbrain is a medical device for improving the diagnostics and prognostics of acute ischaemic stroke

timeisbrain is a medical device for improving the diagnostics and prognostics of acute ischaemic stroke

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human beings using advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed Alya Red, a suite of simulation tools designed for the medical device and pharmaceutical industries. Utilizing a Software-as-a-Service model, Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients. By integrating high-performance computing, computational biomechanics, and data analysis, ELEM's technology enables biomedical companies and clinicians to improve diagnoses, plan treatments, and optimize drug delivery and medical devices.

AcouSort is a Swedish company specializing in the development and sale of laboratory products and integrated solutions that utilize ultrasound technology for the separation, washing, and enrichment of biological samples. Its offerings cater to researchers and life science companies, focusing on the automated preparation of samples such as blood cells, bacteria, and extracellular vesicles. The technology is rooted in acoustofluidics research from the esteemed group led by Professor Thomas Laurell at Lund University's Department of Biomedical Engineering. Key products include AcouTrap, AcouWash, and AcouPlasma, which facilitate efficient handling of microscopic particles in microfluidic channels for research and diagnostic applications.

Selio Medical is focused on developing an innovative medical device aimed at preventing pneumothorax during transthoracic needle biopsies. The company has created a patented smart needle technology that temporarily seals the needle access route into the lung prior to the biopsy procedure. This device is designed to enhance safety and effectiveness for interventional radiologists, making the biopsy process more user-friendly. The Selio prototype has undergone extensive laboratory testing and has demonstrated positive results in pre-clinical in vivo studies, highlighting its potential benefits in clinical settings.

AMT Medical B.V., founded in 2015 and based in Ede, the Netherlands, specializes in developing innovative devices for heart bypass surgery. The company has created the AMT Heart Bypass System, which utilizes the ELANA bypass technique, originally developed by neurosurgeon Prof. Dr. C.A.F. Tulleken and his team. This minimal invasive approach aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, ultimately improving patient outcomes and recovery times. The AMT Heart Bypass System has completed its development and production processes, as well as all pre-clinical trials. A clinical multi-center trial is set to begin in late 2019 or early 2020, marking a significant step in bringing this advanced technology to the medical community.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

AVerto is a medical device manufacturer specializing in telemonitoring technology that focuses on the detection of changes in carotid pulse waves. The company has developed an innovative device that leverages artificial intelligence and proprietary algorithms to analyze blood flow and physiological changes. This technology provides healthcare providers with timely alerts through an accompanying application, which enhances signal quality and reduces false alerts. By integrating advanced signal analysis and deep learning, AVertto's solutions aim to improve patient monitoring and care in clinical settings.

Restore Medical is a medical device company focused on treating congestive heart failure, specifically targeting patients with left ventricle failure. Founded in 2016 and based in Or Yehuda, Israel, the company offers ContraBand, a catheter-delivered implant designed for placement in the pulmonary arteries. This innovative device aims to enhance left ventricle ejection fraction, decrease mitral regurgitation, and restore favorable ventricular geometry. By improving patient outcomes, Restore Medical's solutions contribute to a better quality of life and aim to reduce the rates of hospital readmission among affected individuals.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

Orixha specializes in the development of an innovative cooling device aimed at improving patient outcomes following cardiac arrest. This device utilizes a dedicated liquid ventilator that performs total liquid ventilation by filling the lungs with liquid perfluorocarbons. This method leverages the high gas solubility and large pulmonary surfaces to transform the lungs into an efficient heat exchange chamber with the bloodstream. By doing so, Orixha's technology helps protect vital organs from damage caused by reperfusion, thereby enhancing the prognosis for patients in critical conditions.

Lindhe Xtend specializes in the development and sale of user-friendly prostheses and accessories aimed at enhancing the quality of life for amputees. The company's products are designed to provide a natural and flexible experience, utilizing composite materials that allow for adaptability to various terrains. By collaborating closely with users, Lindhe Xtend focuses on creating solutions that enable individuals to navigate daily challenges with ease, promoting a life of freedom and mobility.

Lindhe Xtend specializes in the development and sale of user-friendly prostheses and accessories aimed at enhancing the quality of life for amputees. The company's products are designed to provide a natural and flexible experience, utilizing composite materials that allow for adaptability to various terrains. By collaborating closely with users, Lindhe Xtend focuses on creating solutions that enable individuals to navigate daily challenges with ease, promoting a life of freedom and mobility.

Limula is a company that has developed an innovative platform technology designed to enhance the scalability of cell therapy production. By integrating a bioreactor and a centrifuge into a single device, Limula's solution enables healthcare providers to manufacture cell and gene therapies in a decentralized manner, bringing these treatments closer to patients. This platform, which includes hardware, software, and consumables, aims to make highly personalized and curative therapies more accessible. The automation of the production process not only increases safety and reproducibility but also allows for the large-scale manufacturing of cell therapy products, thereby addressing the critical need for improved access to gene-engineered therapies.

GlucoSet is a medical device company focused on advancing sensor technology for glucose monitoring in intensive care units (ICUs). Elevated and unstable blood glucose levels in ICU patients can lead to serious complications, including infections, prolonged hospital stays, and increased mortality. To address this issue, GlucoSet has developed an intravascular sensor that provides continuous and precise measurements of blood glucose levels. This innovative system enhances clinicians' ability to normalize glucose levels effectively while minimizing the risk of sudden, dangerously low glucose occurrences. By improving glucose control, GlucoSet aims to reduce complications and healthcare costs associated with ICU patient care.

AuriGen Medical Limited is an electrophysiology and structural heart company based in Dublin, Ireland, founded in 2016. The company focuses on developing innovative left atrial appendage (LAA) implants designed to address the stroke and arrhythmia risks associated with persistent atrial fibrillation (AF). AuriGen's technology targets highly symptomatic patients who are resistant to medication, a demographic that includes over 3 million individuals in the United States and Europe. The rising incidence of AF, particularly among aging populations, underscores the urgent need for effective treatment alternatives. AuriGen's devices incorporate custom LAA occluder implants and are designed to enhance patient outcomes by reducing reliance on anticoagulants and anti-arrhythmic medications. With the annual costs of managing medication-resistant AF running into billions, AuriGen aims to provide cost-effective solutions that improve treatment efficacy and patient quality of life.

Synergia Medical, established in 2013 and based in Mont-Saint-Guibert, Belgium, specializes in developing neurostimulation medical devices. The company is renowned for its innovative optoelectronic neurostimulator platform, which integrates biomaterials, optical components, biosensors, and microelectronics. Synergia's mission is to commercialize next-generation neurostimulation devices, led by a seasoned management team with extensive experience in developing implantable neurostimulators. In a short span of three years, the company achieved ISO13485 certification, created and sold an OEM external neurostimulator for a motorized amputee prosthesis arm, and developed its first version of the NAOS platform. Backed by private investors and public research grants, Synergia has grown to a team of thirteen highly skilled multidisciplinary professionals, focusing on advancing medical devices for neurostimulation using optoelectronics.

Reactive Robotics GmbH, founded in April 2015 and based in Gilching, Germany, specializes in the design, manufacture, and sale of rehabilitation robots aimed at early movement rehabilitation following neurological injuries and orthopedic surgeries. The company focuses on gait rehabilitation for neurological patients and assists orthopedic patients recovering from joint replacements. With a team that has over 12 years of experience in rehabilitation robotics, Reactive Robotics benefits from a robust clinical network and a group of advisors who provide guidance on engineering, legal matters, and medical device registration. Additionally, the company develops AI-driven robotic systems that support very early mobilization therapy, facilitating faster recovery for patients in intensive care units while alleviating the workload of nursing staff.

GlucoSet is a medical device company focused on advancing sensor technology for glucose monitoring in intensive care units (ICUs). Elevated and unstable blood glucose levels in ICU patients can lead to serious complications, including infections, prolonged hospital stays, and increased mortality. To address this issue, GlucoSet has developed an intravascular sensor that provides continuous and precise measurements of blood glucose levels. This innovative system enhances clinicians' ability to normalize glucose levels effectively while minimizing the risk of sudden, dangerously low glucose occurrences. By improving glucose control, GlucoSet aims to reduce complications and healthcare costs associated with ICU patient care.